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Summary
Objective: Since the development of posttraumatic osteoarthritis (OA) is a relatively slow process, estimation of OA risk would be of value
with regard to chondroprotective measures and medication. In this study we investigated the significance of pro-matrixmetalloproteinase-3
(proMMP-3) for this purpose.
Design: Synovial fluid (SF) and serum samples were collected from 259 patients of our trauma clinic at the time of arthroscopy. The extent
of cartilage damage was assessed according to the Outerbridge-score. ProMMP-3 levels in SF and serum were determined by
enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody. Additionally we determined SF and serum levels of total MMP-3
and COMP levels as well as TIMP-1 and -2 concentrations in 40 randomly selected patients by ELISA.
Results: Serum proMMP-3 levels of the total cohort were markedly increased compared to healthy controls (P<0.007). The comparison of
serum and SF lavage proMMP-3 concentrations showed a significant correlation (rs0.41, P<0.0001), however, only 26% of the investigated
samples were increased above normal ranges. The grade of cartilage damage did not correlate with enzyme concentration neither in
patients’ serum nor in SF samples. ProMMP-3 SF concentration was increased early after trauma. Furthermore, proMMP-3 correlated
significantly with total MMP-3 serum and SF levels as well as COMP SF levels.
Conclusions: The measurement of proMMP-3 in serum or SF did not reflect the present cartilage damage and thus appears to have only
minor potential for clinical use, but it should be considered for longitudinal studies, since it may reflect a risk for cartilage degradation in a
subset of patients.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
The possibilities of diagnosing early changes in articular
cartilage to prevent the development of irreversible carti-
lage damage, ultimately leading to osteoarthritis (OA), are
presently limited.
Biochemical markers of cartilage metabolic activity are
attractive as possible easy predictors of OA development.
There are different approaches to determine cartilage deg-
radation, either by measuring catabolic mediators such as
matrix metalloproteinases and aggrecanase1–4, or by de-
tecting cartilage degradation products1,2,4–6. For instance,
cartilage oligomeric matrix protein (COMP) has been pro-
moted for this purpose. However, despite convincing data
for the usefulness of COMP in predicting cartilage
damage7–11, many factors confounding its clinical potential
have been described. Mainly, weak correlations with the
grade of cartilage degradation and its presence only in
early OA stages were seen4,5,8,12,13.
Pro-matrix metalloproteinase-3 (proMMP-3) is the inac-
tive form of metalloproteinase-3 (MMP-3). The measure-
ment of proMMP-3 concentrations may be useful in
predicting cartilage degradation, since this pro-enzyme has
been shown to be elevated in synovial fluid (SF) in condi-
tions of cartilage damage of the knee joint14. One advan-
tage of proMMP-3 may be the higher stability and longer
half life in the circulation, as its affinity to inhibitor proteins,
such as tissue inhibitors of metalloproteinase, may be
much less than that of the active form15,16, saving
proMMP-3 from early elimination out of SF or serum.
We tested the value of proMMP-3 for predicting the
extent of ongoing posttraumatic cartilage damage.
Patients and methods
PATIENTS
Serum and joint fluid samples were obtained from 259
patients after knee injury, who underwent arthroscopy be-
cause of persistent pain or joint instability. Patients with
previous surgery of the knee, radiographic signs of OA or
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established inflammatory joint disease, such as rheumatoid
arthritis, were excluded from the study. None of the patients
had undergone arthroscopy before or had been treated
with intraarticular steroids. The condition of cartilage was
graded by findings at arthroscopy following the
Outerbridge-score from 0–4: 0=no cartilage damage,
1=weakened cartilage without superficial fibrillation, 2=
superficial fibrillation, 3=deep cartilage clefts, 4=bony ero-
sion17. The diagnostic findings included anterior cruciate
ligament (ACL) rupture with or without concomitant lesions
of the medial collateral ligament, isolated meniscal tears
(MEN), and other lesions including plica syndrome, luxation
of patella and isolated cartilage damage (other).
The serum control group consisted of 20 volunteers
(hospital workers) with no history of knee symptoms. Nine
control SF samples were obtained post mortem from organ
donors without a documented joint disease, with macro-
scopically intact articular cartilage. The taking of SF
samples from organ donors was approved by the Ethics
Committee of the University of Vienna.
ACQUISITION OF SERUM AND SF SAMPLES
Blood samples were collected in sterile tubes without
additives before arthroscopy was carried out. Samples
were allowed to clot at room temperature and centrifuged.
Thereafter serum was stored in aliquots at −70°C.
Aspiration of knee joint fluid was done using the pro-
cedure described by Geborek et al.18. Before arthroscopy,
an arthrocentesis of the supralateral pouch was performed.
The native joint fluid was microscopically evaluated and
specimens with signs of inflammation (>1000 cells/mm3)19
were excluded. After aspiration to dryness, 20 ml of physio-
logical saline was injected. After moving the joint five times
between 0 and 90° to assure sufficient distribution of the
fluid in the whole joint compartment, 3 ml of lavage of fluid
was aspired through a new punction-needle.
The joint-lavage samples were centrifuged at 3.000g for
15 min to remove cells and debris. The supernatants were
stored in aliquots at −70°C.
Synovial fluid from organ donors (age range 30 to 56
years, median 44 years) was obtained directly after open-
ing the joint space without any preceding lavage. Thus the
values obtained had to be divided by the factor 20 in order
to compare them to the lavage fluids from posttraumatic
patients.
MARKER ASSAYS
ProMMP-3 in serum and joint-lavage was quantified
by ELISA (BindAzyme™, The Binding Site Limited,
Birmingham, UK), according to the manufacturer’s manual.
In 40 randomly selected patients, as selected by a
computerized randomization program, total MMP-3 and
COMP levels were measured in serum and SF lavage,
using the Quantikine human MMP-3 (total) ELISA kit (R&D
Systems Inc., Minneapolis, MN, USA). COMP concen-
trations were assessed using an ELISA kit (COMP ELISA,
AnaMar Medical AB, Uppsala, Sweden). Since it was
proposed earlier for OA cartilage20,21 that an imbalance
between MMPs and its inhibitors may contribute a possible
pathomechanism in cartilage destruction we additionally
determined Tissue inhibitor of metalloproteinases (TIMP)-1
and -2 levels in the same 40 patients by ELISA (Quantikine
human TIMP-1 and Quantikine human TIMP-2 ELISA kit,
R&D Systems Inc.).
Highly sensitive C-reactive protein (hs-CRP) measure-
ments were available from 86% of the patients using an
immunoturbidimetric assay (Dade-Bering, Vienna, Austria).
STATISTICAL ANALYSIS
The statistical significance of differences in the median
values among the groups was determined by Kruskal–
Wallis one way analysis of variance on ranks, to isolate the
groups that differ from others the pairwise multiple compari-
son procedures (Dunn’s method) was used. Mann–Whitney
rank sum test was used to determine significant differences
between groups. To examine relationships between serum
Fig. 1. Correlation between pro-matrix metalloproteinase-3 (proMMP-3) serum and synovial fluid (SF) lavage levels in 259 patients after
injury of the knee joint. Relationship between serum and SF lavage levels were calculated by Spearman’s test (rs0.41, P<0.0001). The grey
box represents SF control values from organ donors and serum levels from healthy controls.
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and joint-lavage proMMP-3 levels the Spearman’s rank
order correlation was used. A P value less than 0.05 was
considered significant.
Results
SERUM AND SF LAVAGE LEVELS OF PROMMP-3
Serum proMMP-3 levels (median (range): 26 (2–674)
ng/ml) were increased compared to healthy controls (67.4
(42.4–91.9) ng/ml; P<0.007), whereas there was no detect-
able statistical difference of proMMP-3 levels in SF lavage
(400 (6–8000) ng/ml) compared to nine organ donors
(442.8 (282.8–1202.5) ng/ml; P0.8). Moreover, we found
a significant correlation between serum and SF lavage
proMMP-3 concentration of all patients, as calculated by
Spearman’s test (rs0.41, P<0.0001) [Fig. 1], however if
values within the normal ranges (74% of 259 patients) were
excluded, no correlation was seen.
Furthermore we investigated the influence of patient age
and sex on proMMP-3 levels. The patients’ age ranged
from 11 to 69 years with an average of 31.2 years. There
was no independent influence of patients’ age, neither on
serum, nor on SF lavage proMMP-3 concentrations (data
not shown).
Sex was almost equally distributed including 56.8% male
and 43.2% female individuals. We found no significant
difference between the male and the female patients group
in serum (male: 30 (2–674) ng/ml and female: 20 (2–664)
ng/ml) as well as in SF lavage proMMP-3 levels (male 480
(12–8000) ng/ml and female 363 (6–8000) ng/ml).
TEMPORAL PATTERN OF PROMMP-3 CONCENTRATIONS IN
SF LAVAGE AFTER KNEE INJURY
To evaluate a relation between time after injury and
proMMP-3 levels we determined three subgroups: (1) up to
1 week after trauma, (2) 2–8 weeks and (3) >8 weeks after
injury and compared serum and SF lavage proMMP-3
levels. In SF lavage, a significant difference was found for
group 1 (740 (20–8000) ng/ml) compared to groups 2
(327.8 (6–8000) ng/ml; P0.01) and 3 (270 (20–3820)
ng/ml; P0.001) [Fig. 2(A)]. There was no statistically
significant difference between serum proMMP-3 concen-
trations within these groups (Fig. 2(B)).
Fig. 2. Temporal pattern of proMMP-3 levels, 1 week, 2–8 weeks and >8 weeks after knee injury. (A) Concentration of proMMP-3 in synovial
fluid (SF) lavage shows a significant increase up to 1 week after injury compared to the other study groups (P0.01 vs 2–8 weeks;
P0.001 vs >8 weeks). (B) In serum no such significance was detectable. Horizontal lines represent the median for each patients group.
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To test a possible relation between serum proMMP-3
levels and the extent of a possible inflammatory reaction
within the joint, we measured serum levels of highly
sensitive-CRP concentrations of 222 patients. We found no
significant correlation (rs0.048, P<0.5) and furthermore,
there was no correlation between hs-CRP and MMP-3
(rs0.25, P<0.1) as well as between hs-CRP and COMP(rs0.2, P<0.9).
SERUM AND SF LAVAGE PROMMP-3 LEVELS IN CORRELATION
WITH THE GRADE OF CARTILAGE DAMAGE
Depending on the grade of cartilage damage, patients
were divided into five study groups (grades 0–4, according
to the Outerbridge-score). We found no statistical differ-
ences in SF lavage proMMP-3 concentrations between
these five groups [Fig. 3(A)].
SERUM AND SF LAVAGE PROMMP-3 CONCENTRATIONS IN
RELATION TO THE TYPE OF KNEE INJURY
Since knee joint injury involves damage of different joint
structures, we compared the serum and SF lavage
proMMP-3 levels with regard to ruptures of the anterior
cruciate ligament with or without concomitant lesions of the
medial collateral ligament (ACL), isolated meniscal tears
(MEN) and other lesions (other), found at arthroscopy.
Synovial fluid lavage proMMP-3 concentrations were highly
increased in patients with ruptures of the anterior cruciate
ligament (600 (6–8000) ng/ml) compared to meniscal
lesions (280 (12–3820) ng/ml; P<0.01) and others (340
(20–5000) ng/ml; P<0.05). Serum proMMP-3 levels after
knee injury that involved ACL (32 (2–674) ng/ml), MEN (23
(2–664) ng/ml) and others (20 (2–500) ng/ml) were not
significantly different. It is noteworthy that correlations
between serum and SF were significant for all conditions
Fig. 3. Pro-matrix metalloproteinase-3 (proMMP-3) concentrations in (A) synovial fluid (SF) and (B) serum in relation to the grade of cartilage
damage. The degree of cartilage damage was evaluated at arthroscopy and graded following the Outerbridge-score: 0=no cartilage damage
(n153), 1=weakened cartilage without superficial fibrillation (n26), 2=superficial fibrillation (n44), 3=deep cartilage clefts (n29) and
4=bony erosion (n7). There was no statistical significance in proMMP-3 levels, when groups were compared, either in SF lavage, or in
serum. Horizontal lines represent the median for each patients group.
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tested (ACL: rs0.48, P<0.0001; MEN: rs0.42, P<
0.0001; others: rs0.41, P<0.002).
LEVELS OF TOTAL MMP-3 AND COMP IN 40 RANDOMLY SELECTED
PATIENTS
We additionally evaluated the levels of total MMP-3 and
COMP in parallel in 40 patients. As shown for proMMP-3,
we found no dependence of the grade of cartilage damage
on MMP-3 and COMP concentrations in the tested individ-
uals (data not shown). Furthermore, our data revealed no
correlation between serum and SF lavage levels for total
MMP-3 (rs0.27, P<0.09) as well as for COMP (rs0.27,
P<0.08). Matrix metalloproteinase-3 (MMP-3) correlated
significantly with its pro-form on both SF (rs0.54, P<
0.0004) and serum levels (rs0.38, P<0.02) [Fig. 4(A, B)].
When we correlated SF and serum COMP levels with that
of proMMP-3 we found a significant correlation for SF
(rs0.47, P<0.003) [Fig. 4(C, D)] While the concentration of
total MMP-3 and COMP were within the normal ranges
in the 40 posttraumatic patients, proMMP-3 levels were
elevated in 55% of these patients.
BALANCE BETWEEN PROMMP-3, MMP-3 AND TIMP-1 AND TIMP-2
In order to account for the role of the inhibitors of matrix
metalloproteinases, we measuerd TIMP-1 and TIMP-2
levels in SF and serum. Synovial Fluid-TIMP levels are
shown in Fig. 5. While not statistically significant, there was
a trend towards elevated TIMP-1 in posttraumatic SF
lavage. The calculation of ratios between proMMP-3 and
MMP-3 to TIMP-1 and TIMP-2 respectively, shows that the
elevation of proMMP-3 levels in posttraumatic joints is
sustained even when considering TIMP levels [Fig. 5].
Serum levels of TIMP-1 (median (range) 158 (111–241)
ng/ml) and TIMP-2 (141 (93–524) ng/ml) of the posttrau-
matic group (n=40) were within the range observed in the
controls (TIMP-1: 177 (143–229) ng/ml; TIMP-2: 138 (105–
172) ng/ml). The ratio of proMMP-3 vs TIMP-1 and -2 was
elevated in 50% of the patients, whereas the ratio of
MMP-3 vs TIMP-1 and -2 was comparable to controls.
Discussion
MMP-3 (also termed stromelysin-1) is a 57/45 kDa
(latent/active) enzyme22 that hydrolyzes a number of extra-
cellular matrix components, including aggrecan, fibronec-
tin, lamnin, collagens III, IV, IX and X23–25. Moreover,
MMP-3 may contribute indirectly to collagen II breakdown
by activating other MMPs26. The involvement of MMP-3 in
cartilage extracellular matrix degradation is well estab-
lished. MMP-3 has been localized in regions of cartilage
Fig. 4. Correlation between total matrix metalloproteinase-3 (MMP-3), cartilage oligomeric matrix protein (COMP) and pro-matrix
metalloproteinase-3 (proMMP-3) in synovial fluid (SF) lavage and serum of 40 randomly selected patients of our study cohort.
Matrix metalloproteinase-3 (MMP-3) correlated significantly with proMMP-3 in (A) SF and (B) serum. The correlation of COMP and
proMMP-3 was significant only for (C) SF lavage but not for (D) serum. The grey boxes represent SF control values from organ
donors (A, C) and serum levels from healthy controls (B, D).
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degradation27,28 and its endogenous expression by articu-
lar chondrocytes, as well as synovial tissue derived from
OA and rheumatoid arthritis (RA) joints has also been
demonstrated29–34. Much attention has been attributed to
MMP-3 as a marker in inflammatory/degenerative joint
diseases. Increased levels of MMP-3 were found in SF
from OA and RA joints35–38. Measurement of plasma
MMP-3 concentrations in OA patients showed a significant
increase compared to controls39.
ProMMP-3 is the inactive form of MMP-3. In chronic
inflammatory joint diseases such as RA serum levels of
proMMP-3 were increased to a high extent40. Furthermore,
Walakovits et al. demonstrated that within the SF the
majority of the enzyme is present as proMMP-3 after
trauma14. Since, the affinity of proMMP-3 to inhibitor pro-
teins, such as tissue inhibitors of metalloproteinase, may
be much less than that of the active form,15,16 its higher
stability may provide a longer half life in the circulation.
We report a significant correlation of proMMP-3 levels in
SF and serum after knee trauma. This finding parallels the
results of the study of Taylor and colleagues, who demon-
strated a correlation between proMMP-3 SF levels and its
concentration in the circulation in patients with chronic
inflammatory joint disease40. It is of note that serum
proMMP-3 levels of only 68 out of 259 patients (26%) were
above normal ranges, indicating a minor clinical signifi-
cance of this marker. However, when we compared
proMMP-3 with established biochemical markers, MMP-3
and COMP, we found a significant correlation between
proMMP-3 and MMP-3 in serum and SF as well as between
proMMP-3 and COMP in SF. Furthermore, our data show
that proMMP-3 serum concentrations were elevated above
normal levels in 55% of the patients with normal serum
MMP-3 or COMP ranges. After accounting for the concen-
tration of metalloproteinase inhibitors, TIMP-1 and TIMP-2,
the elevation of proMMP-3 remained apparent.
These data suggest a potential role for proMMP-3 as a
marker for cartilage degradation in longitudinal studies.
The question arises which condition may lead to an
increase in proMMP-3 and/or MMP-3 expression. It was
proposed originally, that the separate determination of the
precursor and active forms of MMP-3 may reflect different
processes, proMMP-3 being associated with synovial in-
flammation, and active MMP-3 reflecting cartilage destruc-
tion37. However, both the latent and the active form are
commonly believed to reflect synovial inflammation40–44.
We thus investigated whether an inflammatory reaction
in joints after injury may be associated with proMMP-3
concentrations. While no macroscopically detectable syno-
vitis was described in any of our arthroscopy reports and
the leucocyte numbers in the SF were below 1000 cells/
mm3, we measured hs-CRP serum levels as an ultra-
sensitive marker for ongoing inflammation. Our data reveal
no significant correlation neither with serum proMMP-3, nor
with MMP-3 or COMP, making a major cytokine release
from the joints very unlikely. While formally a local
inflammatory-like process cannot be excluded, hs-CRP
seems not to be a relevant marker for this question.
A positive relationship between the expression of MMP-3
and different stages of OA of the knee was reported earlier
Fig. 5. Ratio of proMMP-3 and MMP-3 vs TIMP-1 and TIMP-2 respectively in posttraumatic joint lavage (n=40) and joint fluid from organ
donors (n=9). The insert-graph shows TIMP-1 and TIMP-2 levels in SF lavage from posttraumatic joints and SF from organ donors. White
symbols represent posttraumatic joint lavage, while solid symbols represent normal joint fluid.
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using immunohistochemistry on cartilage biopsies34. This
data suggested a connection between the amounts of
expressed MMP-3 with the extent of cartilage damage.
When we examined the influence of the degree of cartilage
damage after knee injury on SF and serum proMMP-3
levels, as well as MMP-3 and COMP levels, we detected no
relation between SF or serum enzyme levels and the grade
of cartilage damage. These findings are supported by the
data of Naito and co-workers, who consistently showed no
influence of the grade of knee OA on plasma MMP-3,
MMP-9 and TIMP-1 levels39.
In summary we showed that serum levels of proMMP-3
were elevated in 26% of the posttraumatic patients without
a significant correlation with SF lavage levels. ProMMP-3
was elevated in SF lavage early after trauma, but
proMMP-3 did not indicate the present cartilage damage.
To answer the original question if proMMP-3 can predict
cartilage damage, we suggest that the measurement of
proMMP-3 in serum or SF has only minor clinical rel-
evance, but should not be omitted in longitudinal studies,
since it may be an additional marker for the evaluation of
the risk for OA development in a subset of patients.
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